Search

Your search keyword '"Stig Linder"' showing total 252 results

Search Constraints

Start Over You searched for: Author "Stig Linder" Remove constraint Author: "Stig Linder"
252 results on '"Stig Linder"'

Search Results

1. Elevated Levels of Serum Thymidine Kinase 1 Predict Poor Survival for Patients with Metastatic Prostate Cancer

2. Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer

4. The deubiquitinase USP8 regulates ovarian cancer cell response to cisplatin by suppressing apoptosis

5. Comprehensive Target Screening and Cellular Profiling of the Cancer-Active Compound b-AP15 Indicate Abrogation of Protein Homeostasis and Organelle Dysfunction as the Primary Mechanism of Action

6. Pseudomonas aeruginosa N-3-Oxo-Dodecanoyl-Homoserine Lactone Impacts Mitochondrial Networks Morphology, Energetics, and Proteome in Host Cells

7. A drug screening assay on cancer cells chronically adapted to acidosis

8. Sensitivity of Acute Myelocytic Leukemia Cells to the Dienone Compound VLX1570 Is Associated with Inhibition of the Ubiquitin-Proteasome System

9. Antiproliferative Effects of the Natural Oxadiazine Nocuolin A Are Associated With Impairment of Mitochondrial Oxidative Phosphorylation

10. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.

11. Cytotoxicity of portoamides in human cancer cells and analysis of the molecular mechanisms of action.

12. Elevation of proteasomal substrate levels sensitizes cells to apoptosis induced by inhibition of proteasomal deubiquitinases.

13. Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma

14. Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts.

15. Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters.

16. Supplementary Figures S1-S8 from Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

17. Supplementary materials, Tables S1-S2 from Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

18. Data from Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer

19. Supplementary Figure 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

20. Data from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

21. Supplementary Table 2 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

22. Supplementary Table 3 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

23. Supplementary Figure 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

24. Supplemental Methods from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

25. Supplementary Table 4 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

26. Supplementary Table 1 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

27. Supplementary Figure 2 from Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors

28. Dienone Compounds: Targets and Pharmacological Responses

29. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug

30. Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation

31. Exploring vulnerabilities of quiescent tumor cells by targeting mitochondrial bioenergetics

32. Contributors

33. Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

34. Identification of proteasome inhibitors using analysis of gene expression profiles

35. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570

36. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

37. Caffeic acid phenethyl ester targets ubiquitin-specific protease 8 and synergizes with cisplatin in endometrioid ovarian carcinoma cells

38. Cellular pharmacology studies of anticancer agents

39. Abstract 3000: Zebrafish tumor-derived xenograft-models for improved diagnosis and treatment planning in ovarian cancer patients

40. Proteasome-associated deubiquitinases and cancer

41. Portoamides A and B are mitochondrial toxins and induce cytotoxicity on the proliferative cell layer of in vitro microtumours

42. A novel tumor spheroid model identifies selective enhancement of radiation by an inhibitor of oxidative phosphorylation

43. Cytotoxic unsaturated electrophilic compounds commonly target the ubiquitin proteasome system

44. Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer

45. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries

46. Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics

47. The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage

48. A drug screening assay on cancer cells chronically adapted to acidosis

49. MYC is downregulated by a mitochondrial checkpoint mechanism

50. A systematic multicellular spheroids screening approach lead to the identification of antineoplastic activity in three different plant extracts from the Egyptian flora

Catalog

Books, media, physical & digital resources